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Toll-like receptors (TLRs) and nuclear-binding domain (NOD)-like receptors (NLRs) are sensors of bacte-
rial cell wall components to trigger an immune response. The TLR4 agonist lipopolysaccharide (LPS) is a
strong immune activator leading to sickness and depressed mood. NOD agonists are less active but can
prime immune cells to augment LPS-induced cytokine production. Since the impact of NOD and TLR
co-activation in vivo has been little studied, the effects of the NOD1 agonist FK565 and the NOD2 agonist
muramyl dipeptide (MDP), alone and in combination with LPS, on immune activation, brain function and
sickness behavior were investigated in male C57BL/6N mice.
Intraperitoneal injection of FK565 (0.001 or 0.003 mg/kg) or MDP (1 or 3 mg/kg) 4 h before LPS (0.1 or
0.83 mg/kg) signiﬁcantly aggravated and prolonged the LPS-evoked sickness behavior as deduced from a
decrease in locomotion, exploration, food intake and temperature. When given alone, FK565 and MDP
had only minor effects. The exacerbation of sickness behavior induced by FK565 or MDP in combination
with LPS was paralleled by enhanced plasma protein and cerebral mRNA levels of proinﬂammatory cyto-
kines (IFN-c, IL-1b, IL-6, TNF-a) as well as enhanced plasma levels of kynurenine. Immunohistochemical
visualization of c-Fos in the brain revealed that NOD2 synergism with TLR4 resulted in increased activa-
tion of cerebral nuclei relevant to sickness.
These data show that NOD1 or NOD2 synergizes with TLR4 in exacerbating the immune, sickness and
brain responses to peripheral immune stimulation.
Our ﬁndings demonstrate that the known interactions of NLRs and TLRs at the immune cell level
extend to interactions affecting brain function and behavior.
 2014 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).1. Introduction termed pathogen-associated molecular patterns (PAMPs) (KawaiActivation of the immune systembymicrobial invasion results in
the production of proinﬂammatory cytokines leading to sickness
behavior, an adaptive behavioral response whose prototypical
symptoms comprise a reduction of locomotor activity, anorexia,
and anhedonia (Dantzer, 2004; Dantzer et al., 2008; Hart, 1988).
Microbial invasion is sensed by cells of the innate immune system
through activation of pattern-recognition receptors (PRRs), follow-
ing the recognition of molecular structures speciﬁc for pathogens,and Akira, 2011). The ﬁrst identiﬁed and best characterized PRRs
belong to the family of Toll-like receptors (TLRs); however, other
PRRs such as the nuclear-binding domain (NOD)-like receptors
(NLRs) represent a further group of PRRs playing important roles
in PAMP recognition and immunity (Franchi et al., 2009; Kawai
and Akira, 2011). Unlike NLRs which are intracellular PRRs, TLRs
are associated with the cell membrane.
Lipopolysaccharide (LPS) is a major component of the outer
membrane of Gram-negative bacteria and acts as a predominant
TLR4 agonist (Poltorak et al., 1998; Kawai and Akira, 2011). After
binding to TLR4 it leads to NF-jB and mitogen-activated protein
(MAP) kinase activation and induces a strong cytokine response
(Poltorak et al., 1998; Kawai and Akira, 2011). Thus, LPS is one of
the most widely studied PAMPs triggering acute sickness behavior,
as well as delayed depression-like behavior in rodents (Frenois
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injection of speciﬁc cytokines such as IL-1b (Anisman et al., 2008)
and TNF-a (Bluthe et al., 1991).
The behavioral effects of peripheral immune activation are
mediated via an afferent neural and an endocrine pathway. As part
of the endocrine pathway, cytokines and circulating PAMPs reach
the brain at the level of the choroid plexus and the circumventric-
ular organs and induce the expression of cytokines within the brain
(Dantzer et al., 2000). The peripheral and central effects of immune
activation can be assessed by means of several parameters. First,
immune activation induces c-Fos-like immunoreactivity, an indi-
cator of neuronal activation, within the brain and can provide
insights into the neural networks that subserve sickness symptoms
(Gaykema and Goehler, 2011; Sagar et al., 1995). Second, immune
activation leads to an increase of circulating corticosterone levels
indicating a stimulation of the hypothalamic–pituitary–adrenal
(HPA) axis (Lenczowski et al., 1997). Third, the tryptophan catabo-
lite kynurenine, which is generated by indoleamine-2,3-dioxygen-
ase (IDO) upon activation by cytokines, has emerged as a key
mediator for the induction of anhedonic and anxiety-like behavior
(Haroon et al., 2012; O’connor et al., 2009; Salazar et al., 2012).
Among the more than 20 members of the intracellular NLR fam-
ily, NOD1 and NOD2 are two widely studied receptors recognizing
c-D-glutamyl-meso-diaminopimelic acid (iE-DAP) and muramyl
dipeptide (MDP), respectively (Elinav et al., 2011). Both ligands
are produced during the synthesis or degradation of peptidoglycan,
with MDP being found in Gram-negative and Gram-positive bacte-
ria,while iE-DAP is predominantly foundonGram-negative bacteria
(Chamaillard et al., 2003; Grimes et al., 2012;Mo et al., 2012). NOD1
can also be activated by the synthetic agonist FK565 (Watanabe
et al., 1985). Similar to the activation of TLR4, NOD1 and NOD2 acti-
vation results in NF-jB- and MAP kinase-dependent inﬂammatory
responses (Elinav et al., 2011). Although NOD agonists are less
potent in releasing cytokines than LPS, they are able to potentiate
cytokine release induced by LPS challenge in innate immune cells
(Le Contel et al., 1993; Netea et al., 2005; Wang et al., 2001;
Wolfert et al., 2002). The synergistic induction of cytokine produc-
tion can also be observed in vivo extending to endotoxin shock, with
profoundhypothermia as one of its hallmarks (Krakauer et al., 2010;
Takada and Galanos, 1987).
While there are some reports that MDP induces sleep and anor-
exia (Fosset et al., 2003; Johannsen et al., 1990; Von Meyenburg
et al., 2004), the impact of NOD1 and NOD2 activation on behavior
and related brain function has been little studied. Likewise, it is lar-
gely unknown whether the interaction of NOD1 and NOD2 stimu-
lation with the TLR4 agonist LPS at the immune level has a bearing
on behavior and cerebral activity (Mccusker and Kelley, 2013).
Since in infection both NLRs and TLRs may be activated in paral-
lel, it was the primary aim of the present study to examine the
effects of NOD1 and NOD2 activation, alone and in combination
with the TLR4 agonist LPS, on sickness, behavior and cerebral c-
Fos expression in order to visualize someof the brain nuclei relevant
to sickness. The secondary objectivewas to analyze potential mech-
anisms behind the synergistic effects of NOD1, NOD2 and TLR4 acti-
vation on sickness and behavior. To this end, the effects of NOD1,
NOD2 and TLR4 activation on inﬂammatory indices such as periph-
eral and central cytokine production and plasma kynurenine/tryp-
tophan ratio were characterized. In addition, HPA axis activation
was assessed by measuring circulating corticosterone levels.
2. Materials and methods
2.1. Experimental animals
The study was carried out with male C57BL/6N mice from
Charles River Laboratories (Sulzfeld, Germany) at the age of10 weeks. The animals were either kept in groups of 2 or singly
housed in the institutional animal house. Light conditions (lights
on at 6:00 h, lights off at 18:00 h), temperature (set point 22 C)
and relative air humidity (set point 50%) were tightly controlled.
Standard laboratory chow and tap water were provided ad libitum
throughout the study.
2.2. Ethics statement
The experimental procedures and number of animals used were
approved by an ethical committee at the Federal Ministry of Sci-
ence and Research of the Republic of Austria (BMWF-66.010/
0119-II/3b/2011) and conducted according to the Directive of the
European Communities Council of 24 November 1986 (86/609/
EEC). The experiments were designed in such a way that the num-
ber of animals used and their suffering was minimized.
2.3. Reagents
The chemically synthesized NOD1 agonist FK565 was provided
by Astellas Pharma Inc. (Ibaraki, Japan) (Watanabe et al., 1985).
MDP (N-acetylmuramyl-L-alanyl-D-isoglutamine hydrate, cata-
logue number A9519, Sigma–Aldrich, Vienna, Austria) was used
as synthetic NOD2 agonist and LPS extracted from Escherichia coli
0127:B8 (puriﬁed by gel-ﬁltration chromatography, catalogue
number L3137, Sigma–Aldrich, Vienna, Austria) was used as a
TLR4 agonist.
2.4. Behavioral testing
The experiments were started after the animals had become
accustomed to the institutional animal house over the course of
at least 2 weeks. Prior to the behavioral tests, the mice were
allowed to adapt to the test room (lights on at 6:00 h, lights off
at 18:00 h, set points 22 C and 50% relative air humidity, maximal
light intensity 100 lux) for at least one day.
2.4.1. LabMaster system + sucrose preference
The pattern of locomotion, exploration, feeding as well as
sucrose preference (SP) were assessed with the LabMaster system
(TSE Systems, Bad Homburg, Germany), allowing continuous
recording of the animals without intervention by any investigator,
as described previously (Painsipp et al., 2013). The LabMaster sys-
tem consisted of test cages (type III, 42.0  26.5  15.0 cm,
length width  height), surrounded by two external infrared
frames and a cage lid equipped with three weight transducers.
For recording locomotion and exploration, the two external infra-
red frames were positioned in a horizontal manner above one
another at a distance of 4.3 cm, with the lower frame being ﬁxed
2.0 cm above the bedding ﬂoor. The bottom frame was used to
record horizontal locomotion of the mice, whereas the top frame
served to record vertical movements (rearing, exploration). The
measures of activity (locomotion, exploration) were derived from
the light beam interruptions (counts) of the corresponding infrared
frames (Painsipp et al., 2013). The three weight transducers were
employed to quantify ingestive behavior. To this end, a feeding
bin was ﬁlled with standard rodent chow (altromin 1324 FORTI,
Altromin, Lage, Germany). In order to assess SP, one drinking bottle
was ﬁlled with tap water and one with a 1% sucrose solution and
the bottles were each attached to a transducer on the cage lid for
the total duration of the experiment. SP was calculated using the
formula: sucrose intake/(sucrose intake + water intake). In a few
cases in which the ﬂuid bottles got obstructed, the data were
excluded from analysis.
Each test parameter was collected over a 24 h interval and
activity scores and food intake recorded during the day before
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injection expressed as a percentage of the pre-injection score.
2.4.2. Open ﬁeld (OF) test
The OF consisted of a box (50  50  30 cm) made of opaque
gray plastic and was illuminated by 35 lux at ﬂoor level (Painsipp
et al., 2013). The ground area of the box was divided into a
36  36 cm central area and the surrounding border zone. Mice
were individually placed in the center of the OF, and their behavior
during a 5 min test period was tracked by a video camera posi-
tioned above the center of the OF and recorded with the software
VideoMot2 (TSE Systems).
2.4.3. Forced swim test (FST)
Mice were individually placed in glass beakers (inner diameter
18 cm, height 27 cm, capacity 5 l) containing tap water at 25 C
(Painsipp et al., 2011). The water depth was 20 cm, which pre-
vented the mice from touching the bottom of the beaker with their
paws or the tail. Mice were tested for 6 min and the time of immo-
bility, swimming and climbing was scored by a trained observer
blind to the treatment. Mice were considered immobile when
ﬂoating passively in the water, performing only those movements
required to keep their heads above the water level (Cryan et al.,
2002).
2.4.4. Tail suspension test (TST)
Mice were suspended by their tail with a 1.9 cm wide strapping
tape (Leukotape classic; BSN Medical S.A.S., Le Mans, France) to a
lever for 6 min, and their behavior was recorded by a video camera.
A trained blinded observer analyzed the video recordings with the
VideoMot2 software (TSE Systems) event monitoring module for 3
types of behavior: swinging, curling and immobility. The mouse
was considered swinging when it continuously moved its paws
while keeping the body straight and/or moving the body from side
to side. The mouse was considered curling when the mouse
twisted its trunk (Berrocoso et al., 2013). The time spent swinging,
curling and being immobile was calculated. Mice which climbed
over their tails were excluded as they had learnt that escape is
possible (Cryan et al., 2005).
2.5. Body temperature
The temperature of the mice was measured with a digital ther-
mometer (BAT-12, Physitemp Instruments, Clifton, New Jersey,
USA) equipped with a rectal probe for mice. The temperature
recordings were taken between 16:00 and 17:00 h.
2.6. Experimental protocols
Three different protocols were used (Fig. 1). For details on the
choice of dosing and timing of injections see Sections 2.7 ‘‘Dosing’’
and 2.8 ‘‘Timing of injections’’.
In protocol 1 (experiment 1.1), the LabMaster system (TSE
Systems) was employed to analyze the effects of MDP (1 mg/kg),
FK565 (0.001 mg/kg), LPS (0.1 mg/kg), MDP + LPS and FK565 + LPS
on the daily pattern of locomotion, exploration, feeding and SP in
singly housed mice (Painsipp et al., 2013). The animals were habit-
uated to the drinking bottles used in the LabMaster system and to
single housing for 7 days before placing them in the cages of the
LabMaster system (Fig. 1). Another 3 days of habituation were
warranted in the test cages of the LabMaster system before
injection of PRR agonists (n = 8).
Protocol 2 was used to carry out 2 separate experiments (Fig. 1).
Experiment 1 of protocol 2 (experiment 2.1) was designed to inves-
tigate the effects of MDP (3 mg/kg), FK565 (0.003 mg/kg), and the
frequently used dose of LPS (0.83 mg/kg), MDP + LPS andFK565 + LPS on the sickness response. For this purpose body tem-
perature and weight were measured immediately before treatment
and body temperature was measured again 4 h post-injection.
An additional measurement of body weight was taken 21 h
post-injection after the animals had been subjected to the open
ﬁeld (OF) test (n = 8). In a separate experiment (experiment 2.2),
mice were euthanized 3 h after injection of PRR agonists (Fig. 1)
and the brains were collected for immunohistochemical visualiza-
tion of c-Fos expression in select brain regions (n = 3–5). Following
euthanasia the brains were removed, put on dry ice and stored at
70 C until use.
Protocol 3 was used in 3 separate experiments (Fig. 1) in which
the effects of MDP and FK565 in combination with the lower dose
of LPS (0.1 mg/kg) were investigated. In experiment 3.1 body tem-
perature and weight were measured before treatment and the
body temperature was measured again 4 h post-injection. The OF
test was conducted 21 h after the treatment and body weight
was measured after the OF test (Fig. 1). Subsequently the animals
were subjected to the tail suspension test (TST) for 6 min (25.5 h
post-injection) and euthanized 30 min after start of the TST. Blood
was sampled to measure the plasma levels of cytokines, corticoste-
rone, kynurenine and tryptophan (Fig. 1). In addition, the brains
were collected, frozen in 70 C cold 2-methyl butane (Fisher
Scientiﬁc, Leicestershire, UK) and stored at this temperature until
measurement of cytokines (n = 7–8).
In experiment 3.2 mice (Fig. 1) were euthanized 3 h after injec-
tion of PRR agonists to record the levels of circulating and brain
cytokines and circulating corticosterone without interference by
any behavioral test (n = 7–8).
In a further experiment (experiment 3.3) singly housed mice
were subjected to the forced swim test (FST) 21 h post-injection,
since depression-like behavior has been shown to be modiﬁed by
different housing conditions (Painsipp et al., 2011) (n = 7–8).
2.7. Dosing
All compounds were dissolved in pyrogen-free sterile saline
(0.9% NaCl) and pyrogen-free sterile saline injected intraperitone-
ally (i.p.) at the same volume (50 lL/10 g body weight) was used
as vehicle (VEH) control.
For the analysis of the interaction between NOD agonists and
LPS, two doses of LPS were examined. First, the widely used dose
of 0.83 mg/kg LPS inducing the full spectrum of sickness (Frenois
et al., 2007; Painsipp et al., 2011) was used. Since, in combination
with the NOD agonists, this dose of LPS led to a marked decrease in
body temperature and locomotion, while a ceiling effect was
observed with other parameters, a lower dose of 0.1 mg/kg LPS
was also tested.
The doses of the NOD agonists (see below) were chosen on the
basis of their immunological effects in vivo (Parant et al., 1995;
Shikama et al., 2011) and the results of pilot experiments. Thus,
doses of 1 mg/kg (LabMaster studies) and 3 mg/kg (ex LabMaster
studies) of MDP and 0.001 mg/kg (LabMaster studies) and
0.003 mg/kg (ex LabMaster studies) of FK565 were used in order
to minimize adverse event rates when combined with the
0.83 mg/kg dose of LPS. Lower doses of the PRR agonists were
administered in the LabMaster system because pilot experiments
had shown that mice kept singly in the LabMaster system were
more sensitive to the treatments than group-housed animals.
2.8. Timing of injections
Mice receiving just one of the compounds (MDP, FK565 or LPS)
were ﬁrst injected with saline followed by the respective com-
pound 4 h later. The ﬁrst injection was given 3 h after start of the
light phase. In experiments involving combination treatments,
Fig. 1. Experimental groups and time lines. In protocol 1, the effects of the PRR agonists on daily activity were assessed in the LabMaster system. In protocol 2, the effects of
MDP and FK565 alone and the combination of MDP or FK565 with the higher dose of LPS (0.83 mg/kg) on sickness and central c-Fos expression were evaluated. In protocol 3,
the effects of MDP and FK565 alone and the combination of MDP or FK565 with the lower dose of LPS (0.1 mg/kg) on sickness, mood and inﬂammation-related parameters
were analyzed. Time zero represents the time of injection and was consistent across all experiments. Abbreviations: CORT = corticosterone, KYN/TRP = kynurenine/
tryptophan ratio, FST = forced swim test, OF = open ﬁeld, Temp = temperature, TST = tail suspension test.
A. Farzi et al. / Brain, Behavior, and Immunity 44 (2015) 106–120 109MDP + LPS and FK565 + LPS were given with a time lag of 4 h
between injection of the NOD and TLR agonist, since this timing
has been shown to have the strongest priming effect on the
immune system (Takada et al., 1990; Takada and Galanos, 1987).
Sickness responses were examined 3–4 h after injection and
depression-like behavior 21–26 h post-treatment. The time points
for the recording of the sickness responses were chosen according
to the known time course of the sickness response to MDP or LPS
(Frenois et al., 2007; Engeland et al., 2003). Sickness behavior has
been shown to pass into depression-like behavior 1 day after injec-
tion of LPS (0.83 mg/kg), which was the reason for choosing the
second time point (Frenois et al., 2007). Since MDP or FK565 alone
did not induce behavioral changes in experiment 2.1 and only
induced a modest cytokine response 3 h post-treatment, the single
treatment with MDP or KF565 was not investigated in experiments
3.1 and 3.2.
2.9. Blood sampling
Mice were deeply anesthetized with pentobarbital (150 mg/kg
i.p.). Blood was sampled by cardiac puncture using citrate (3.8%)
as an anticoagulant. Following centrifugation for 10 min at 4 C
and 1000g, blood plasma was collected and stored at 70 C until
assay.
2.10. Circulating corticosterone
The plasma levels of corticosterone were determined with an
enzyme immunoassay kit (Assay Designs, Ann Arbor, Michigan,USA). According to the manufacturer’s speciﬁcations, the sensitiv-
ity of the assay is 27 pg/mL, and the intra- and inter-assay coefﬁ-
cient of variation amounts to 7.7% and 9.7%, respectively.
2.11. Kynurenine and tryptophan
Kynurenine and tryptophan were measured in plasma samples
by high-performance liquid chromatography (HPLC) with ultravio-
let detection (Herve et al., 1996). In brief, 100 lL plasma samples
were deproteinized by adding of 100 lL of 5% (v/v) perchloric acid.
After vortexing and 5 min centrifugation at 11,000g, 20 lL of the
clear supernatant was injected in the chromatographic system.
Separations were achieved on a Chromolith RP18e column
(100  4.6 mm, 5 lm, Merck Darmstadt, Germany) at 30 C by iso-
cratic elution with a mobile phase consisting of 50 mmol/L ammo-
nium acetate, 250 mol/L zinc acetate and 3% (v/v) acetonitrile (pH
4.9) at a ﬂow rate of 0.8 mL/min. Kynurenine and tryptophan were
detected on a LaChrom UV-Detector Merck HITACHI L-7400 at
235 nm. Acquisition and processing of the chromatograms were
performed using a Merck Hitachi LaChrom-D-7000 HPLC-System
Manager software (VWR International GmbH/Scientiﬁc Instru-
ments, Darmstadt, Germany). The concentrations were determined
by peak-height measurement against external standards. This
method has been validated according to international guidelines
(Center for Veterinary Medicine (CVM), 2001). All reagents were
of p.A. grade (Merck, Darmstadt, Germany). The within-day coefﬁ-
cient of variation (CV) at different concentrations ranged from 1.7%
to 4.3%, for kynurenine and 0.7% to 2.9% for tryptophan. The
between day CVs were 2.0–5.4% and 6.3–9.3% respectively.
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Concentrations of IFN-c, IL-1b, IL-6 and TNF-a were simulta-
neously quantiﬁed in plasma using the ProcartaPlex™ immunoas-
say (eBioscience, San Diego, CA, USA). Cytokine concentrations
were determined using analyte speciﬁc capture beads coated with
target-speciﬁc capture antibodies according to the manufacturer’s
speciﬁcations. The analytes were detected by biotinylated analyte-
speciﬁc antibodies. Following binding of the ﬂuorescent detection
label (SA-PE), the reporter ﬂuorescent signal was measured with
the Bio-Plex 200 multiplex suspension array system employing
Luminex xMAP technology in combination with the Bio-Plex 5.0
Software (Bio-Rad, Hercules, CA).
Standard curves for each analyte were generated by using the
reference analyte concentration supplied and concentrations were
calculated using a ﬁve-parameter logistic curve-ﬁtting method.
Cytokines that were not detected were assigned a value of zero.
The sensitivity for the respective cytokines was: IFN-c: 0.09
pg/mL, IL-1b: 0.14 pg/mL, IL-6: 0.21 pg/mL, TNF-a: 0.39 pg/mL.
Plasma samples of experiment 3.3 were run in duplicate. Since
the coefﬁcient of variance for the duplicate samples was small,
single samples were run subsequently.
2.13. RNA extraction and reverse transcription
LPShas been reported to induceaubiquitousupregulationof cyto-
kine mRNA expression in discrete brain regions (O’connor et al.,
2009). Thus, one part of a hemibrain (Bregma +0.50 to2.70) weigh-
ing 50–60mg was dissected on a cold plate and homogenized in
MagnaLyser bead tubes (Catalogue number 03358 941 001, Roche
Diagnostics, Rotkreuz, CH) using the MagnaLyser centrifuge (Roche
Diagnostics). Total RNA was extracted in TRIzol reagent (Catalogue
number 15596018, Life Technologies, Carlsbad, CA) and randomly
tested for quality on the BioAnalyzer BA2100 (Agilent, Foster City,
CA) with the RNA 6000 Nano LabChip Kit (Catalogue number 5067-
1511, Agilent, Foster City, CA). The RIN (RNA Integrity Number) of
all tested samples ranged between 7.9 and 8.7. All RNA sampleswere
reverse transcribed simultaneously in the Thermocycler ‘MyCycler’
(Bio-Rad Laboratories, Hercules, CA), using the High Capacity cDNA
Reverse Transcription Kit (Catalogue number 4368813, Life Technol-
ogies) according to manufacturer instructions.
2.13.1. Real-time RT-PCR
Real-time RT-PCR was performed on a LightCycler480 System
using TaqMan gene expression assays for TNF-a (Mm004432
58_m1), IL-1b (Mm00434228_m1), IFN-c (Mm01168134_m1), IL-6
(Mm00446190_m1), Gapdh (Mm999999_g1) and Actb (Mm0060
7939_s1) purchased from Life Technologies (Catalogue number
4331182). For the real-time RT-PCR setup the TaqMan Gene Expres-
sion Master Mix (Catalogue number 4369016, Life Technologies)
was used. Reactions were carried out in triplicates according toman-
ufacturer instructions using a 20 ng cDNA template for each reaction.
As negative controls, ampliﬁcations without reverse transcription or
template were included. Quantitative measurement of target gene
levels relative to controls was performed with the 2DDCt method
(Schmittgen and Livak, 2008). Gapdh and Actb were used as endoge-
nous housekeeping genes.
2.14. c-Fos immunohistochemistry
The activation of neurons in select nuclei and cortical areas of
the brain was visualized by c-Fos immunohistochemistry 3 h after
injection of PRR agonists. Immunohistochemistry was performed
according to a slightly modiﬁed version of the protocol provided
by Sundquist and Nisenbaum (2005) and described by
Reichmann et al. (2013). The primary antibody used was rabbitpolyclonal anti-c-Fos SC-52 (Santa Cruz Biotech, Santa Cruz,
California, USA, 1:2000 dilution). As the secondary antibody, the
biotinylated goat anti-rabbit IgG (Vectastain Elite ABC Kit, Vector
Laboratories, 1:200 dilution) was used. The sections were incu-
bated in avidin–biotin complex (Vectastain Elite ABC Kit, Vector
Laboratories) and developed with 3,3-diaminobenzidine substrate
(DAB substrate kit for peroxidase, Vector Laboratories).2.14.1. Cell counting and quantiﬁcation
The immunohistochemically processed brain sections were
examined with a light microscope (Axiophot, Zeiss, Oberkochen,
Germany) coupled to a computerized image analysis system
(MCID Basic, version 7.0, Imaging Research Inc., Brock University,
St. Catharines, Ontario, Canada) as described previously
(Reichmann et al., 2013). While in the paraventricular nucleus
of the hypothalamus (PVN) and the granular cell layer of the
dentate gyrus all c-Fos positive cells were counted, the number
of c-Fos labeled cells in the other regions of interest (ROIs) was
quantitated within a square of 200  200 lm, and the c-Fos
labeled cells of the subfornical organ were quantitated within a
square of 400  400 lm. One section was counted bilaterally to
quantitate the number of c-Fos positive cells in the dorsal part
of the bed nucleus of the stria terminalis (BNSTd) (Bregma
+0.38 to +0.14), while two consecutive sections were counted
bilaterally to quantitate the number of c-Fos positive cells in
the ventral part of the bed nucleus of the stria terminalis (BNSTv)
(Bregma +0.50 to +0.14), the paraventricular nucleus of the hypo-
thalamus (PVN) (Bregma 0.58 to 0.94), the insula (Bregma
+0.38 to +0.14), and the subfornical organ (SFO) (Bregma 0.58
to 0.70). Three consecutive sections were counted bilaterally
to quantitate the number of c-Fos positive cells in the central
amygdala (CeA) (Bregma 1.34 to 1.70), the supraoptic nucleus
(SO) (Bregma 0.70 to 1.06), and the dentate gyrus (DG)
(Bregma 1.34 to 1.94). The cell counts obtained for each ROI
in the different sections of each animal were averaged to calcu-
late the mean number of c-Fos-positive cells within a particular
brain region of that animal. These average values/brain region
of each animal were used for statistical analysis.2.15. Statistics
Statistical evaluation of the results was made with SPSS 20
(SPSS Inc., Chicago, Illinois, USA). In general, the data were ana-
lyzed by one-way or two-way analysis of variance (ANOVA), as
appropriate, in some cases for repeated measurements. Two-way
ANOVA was performed with the NOD agonists (VEH, MDP,
FK565) and LPS (VEH, LPS) as the between subject variables in
order to reveal signiﬁcant main factor effects or interactions
denoted as NOD  LPS interactions. The homogeneity of variances
was assessed with the Levene test. In case of sphericity violations
the Greenhouse–Geisser correction was applied. Post-ANOVA anal-
ysis of group differences was performed with the Tukey HSD (hon-
estly signiﬁcant difference) test, when the variances were
homogeneous, and with the Games–Howell test, when the vari-
ances were unequal. In case of a non-parametric distribution of
the parameters, statistical differences among groups were deter-
mined with the Kruskal–Wallis test and post-hoc analysis of group
differences was performed with the Mann–Whitney test. p values
were adjusted for multiple comparisons with the Bonferroni cor-
rection. Probability values of p < 0.05 were regarded as statistically
signiﬁcant and p < 0.1 were regarded as a trend. All data are pre-
sented as means + SEM, n referring to the number of mice in each
group.
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3.1. Effects of MDP, FK565 and LPS on daily levels of locomotion,
exploration, food intake and SP
MDP, FK565 and LPS altered locomotion, exploration, food intake
and SP in a compound-, combination- and time-dependent manner
(Fig. 2). Repeated measures ANOVA revealed a signiﬁcant interac-
tion of NOD (VEH, MDP, FK565)  LPS (VEH, LPS)  time (days
post-treatment) for the variation in locomotion (F(5.661,116.05) =
2.457, p < 0.05). The same was true for exploratory behavior
(F(5.250,110.25) = 2.470, p < 0.05). Likewise, there was a signiﬁcant
NOD  LPS  time interaction for the differences in food intake
(F(5.025,105.52) = 5.244, p < 0.001). SP depended on time
(F(1.130,39.55) = 27.838, p < 0.001), with a signiﬁcant interaction with
LPS (F(1.130,39.55) = 18.397, p < 0.001) and an interaction with the
NOD agonists by trend (F(2.260,39.55) = 2.339, p = 0.10).
Post-hoc analysis revealed signiﬁcant NOD  LPS interactions
on day 1 and 2 post-treatment. While MDP (1 mg/kg) and FK565
(0.001 mg/kg) alone did not induce any signiﬁcant changes in loco-
motion, LPS (0.1 mg/kg) led to a decrease of locomotion for 2 days
after injection when compared with the VEH-treated group. Com-
bination of MDP + LPS attenuated locomotion compared to treat-
ment with MDP or LPS alone during day 1 and 2 post-treatment
(Fig. 2A). Likewise, the combination of FK565 + LPS signiﬁcantly
decreased locomotion when compared with FK565 or LPS alone.
Post-hoc analysis of the changes in exploration disclosed a signiﬁ-
cant NOD  LPS interaction on day 1 and 3 post-treatment, while
there was only a trend for interaction on day 2 (p = 0.1). Speciﬁ-
cally, MDP + LPS and FK565 + LPS decreased exploration when
compared with LPS or MDP and FK565, respectively (Fig. 2B).
A signiﬁcant NOD  LPS interaction was evident for food intake
on day 1 and 2 post-treatment (Fig. 2C). While the effect of FK565
did not reach statistical signiﬁcance after correcting for multiple
testing, LPS diminished food intake 1 day after treatment when
compared to VEH. Again, MDP + LPS and FK565 + LPS further atten-
uated food intake 1 day post-treatment compared to MDP andFig. 2. Effects of MDP, FK565 and LPS on daily levels of locomotion (A), exploration (B), fo
FK565 (0.001 mg/kg), LPS (0.1 mg/kg), MDP + LPS or FK565 + LPS were injected i.p. as indic
and C) and 5 days after injection. The values are means ± SEM, n = 8. Post-hoc analysis of s
#p < 0.05, ##p < 0.01, MDP + LPS or FK565 + LPS versus MDP, FK565 or LPS.FK565, respectively. Both combinations also led to a decrease
of food intake when compared with LPS (Fig. 2C). On day 2 post-
treatment food intake was still decreased in the FK565 + LPS group
compared to the FK565 or LPS groups, while the effect of
MDP + LPS did not reach signiﬁcance after correcting for multiple
testing.
Unlike LPS, MDP + LPS or FK565 + LPS led to a nominal decline
of SP on day 1 post-treatment, but the interaction of LPS with
the NOD agonists did not reach statistical signiﬁcance (Fig. 2D).
3.2. Effects of MDP and FK565 alone and in combination with LPS on
body temperature and weight
MDP, FK565 and LPS interacted with each other in modifying
body temperature but not body weight (Fig. 3). Two-way ANOVA
revealed a signiﬁcant NOD  LPS interaction for the changes in
body temperature (F(4,65) = 20.413, p < 0.001) (Fig. 3A). Post-hoc
analysis showed that neither MDP (3 mg/kg), FK565 (0.003 mg/
kg) nor the two doses of LPS induced changes of body temperature
4 h post-treatment. In contrast, combined treatment with
MDP + LPS (0.83 mg/kg) and FK565 + LPS (0.83 mg/kg) evoked a
strong hypothermic response compared to single treatment with
the NOD agonists or LPS (Fig. 3A). Also the combination of MDP
or FK565 with the lower dose of LPS (0.1 mg/kg) slightly decreased
body temperature, the effect of MDP + LPS (0.1 mg/kg) reaching
statistical signiﬁcance when compared to MDP alone (Fig. 3A).
The effects on body weight differed from those on body temper-
ature. Thus, a NOD  LPS interaction was not evident for the differ-
ences in weight (Fig. 3B). Two-way ANOVA showed that weight
loss depended solely on LPS (F(2,67) = 166.200, p < 0.001) (Fig. 3B).
3.3. Effects of MDP and FK565 alone and in combination with LPS on
behavior in the OF
The behavior in the OFwasmodiﬁed byMDP, FK565 and LPS in a
compound-, combination- and time-dependentmanner (Fig. 4). The
OF test was used to assess anxiety-like behavior as deduced fromod intake (C) and sucrose preference (D) in male mice. Saline (VEH), MDP (1 mg/kg),
ated. The graphs show the daily levels of activity for 1 day before (set as 100% in A, B
igniﬁcant NOD  LPS interactions in 2-way ANOVA: ⁄p < 0.05, ⁄⁄p < 0.01, versus VEH.
Fig. 3. Effects of MDP (3 mg/kg), FK565 (0.003 mg/kg) and LPS (doses as indicated) to reduce body temperature (A) and weight (B) in male mice. The graphs show the change
in temperature 4 h post-treatment and body weight 21 h post-treatment. Body temperature and weight were measured before treatment and 4 and 26 h post-injection,
respectively. The weight loss induced by the treatment is expressed as a percentage of the body weight measured pre-treatment. The values are means + SEM, n = 15 for VEH
(merged from 2 separate experiments), n = 7–8 for other groups. Post-hoc analysis of signiﬁcant NOD  LPS interactions in 2-way ANOVA: ##p < 0.01, MDP + LPS versus MDP
or FK565 + LPS versus FK565. §§p < 0.01, MDP + LPS and FK565 + LPS versus LPS (0.83 mg/kg). Main factor effects without NOD  LPS interactions: ap < 0.01, LPS versus VEH.
bp < 0.01, LPS 0.83 mg/kg versus LPS 0.1 mg/kg.
Fig. 4. Effects of MDP (3 mg/kg), FK565 (0.003 mg/kg) and LPS (doses as indicated) on behavior in the OF 21 h post-treatment in male mice. The graphs show the time spent in
the central area (A + D), the number of entries into the central area (B + E) and the total distance traveled (C + F) during the 5 min test session. The values are means + SEM,
n = 7–8. (A–C): Post-hoc analysis of signiﬁcant NOD  LPS interactions in 2-way ANOVA: ⁄p < 0.05, versus VEH. ##p < 0.01, MDP + LPS versus MDP or FK565 + LPS versus
FK565. §§p < 0.01, MDP + LPS or FK565 + LPS versus LPS. Main factor effects without NOD  LPS interactions: ap < 0.01, LPS versus VEH. (D–F): One-way ANOVA: ⁄p < 0.05,
⁄⁄p < 0.01, versus VEH.
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area of the OF and locomotion as deduced from the traveling dis-
tance (Fig. 4). In experiments with the higher dose of LPS
(0.83 mg/kg), two-way ANOVA revealed a signiﬁcant NOD  LPS
interaction for the changes in locomotion (F(2,42) = 3.168, p 6 0.05).
Post-hoc analysis showed that while the NOD agonists did not
impact on locomotion, treatment with LPS (0.83 mg/kg) slightly
decreased the traveling distance in the OF (Fig. 4C). Furthermore,
combined treatment with MDP (3 mg/kg) + LPS (0.83 mg/kg) or
FK565 (0.003 mg/kg) + LPS (0.83 mg/kg) further diminished the dis-
tance traveled when compared with LPS alone, or MDP and FK565,
respectively (Fig. 4C). The entries made into the center of the ﬁeld
depended on LPS (F(1,42) = 31.001, p < 0.001), while the effect of
theNOD agonists and their interactionwith LPS did not reach signif-
icance (Fig. 4B). The time spent in the central area of the OF was not
signiﬁcantly affected by any of the compounds (Fig. 4A).
In experimentswith the lower dose of LPS (0.1 mg/kg), LPS alone,
MDP + LPS (0.1 mg/kg), as well as FK565 + LPS (0.1 mg/kg) reducedthe time spent in the central area of the ﬁeld (Fig. 4D) and the entries
made to the central area (Fig. 4E) without affecting the total dis-
tance traveled (Fig. 4F). The combination of FK565 + LPS had the
most pronounced effects. While the time in the central area was
reduced in all groups (F(3,25) = 7.176, p = 0.001) (Fig. 4D), the entries
made to the central area of the ﬁeld were solely reduced by
FK565 + LPS (F(3,25) = 6.256, p < 0.01) (Fig. 4E).
3.4. Effects of MDP, FK565 and LPS alone and in combination on
depression-like behavior in the FST and TST
LPS (0.1 mg/kg) did not change any behavioral parameter in the
FST. In contrast, combined treatment with MDP + LPS and
FK565 + LPS induced a slight increase of immobility and a decrease
of the duration of time spent swimming, but these changes did not
reach statistical signiﬁcance (Table 1). Likewise, in the TST there
were no signiﬁcant changes in the duration of immobility, swing-
ing or curling by any of the treatments (Table 1).
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circulating cytokines
MDP, FK565 and LPS, alone and in combination, had distinct
effects to enhance the circulating levels of proinﬂammatory cyto-
kines (Fig. 5). Three hours after injection, there was a signiﬁcant
NOD  LPS interaction with regard to the circulating levels of IFN-
c (F(2,39) = 6.004, p < 0.01), IL-1b (F(2,40) = 6.274, p < 0.01), IL-6
(F(2,40) = 7.092, p < 0.01) and TNF-a (F(2,40) = 7.665, p < 0.01)
(Fig. 5A–D). Post-hoc analysis revealed that treatment with MDP
(3 mg/kg) or FK565 (0.003 mg/kg) alone did not induce signiﬁcant
increases in the plasma levels of the cytokines measured (Fig. 5).
LPS (0.1 mg/kg) alone increased circulating IL-1b and IL-6 levels
compared to VEH (Fig. 5B and C). In contrast, treatment with MDP
or FK565 + LPS increased the levels of all circulating cytokines under
study relative to MDP and FK565, respectively (Fig. 5A–D). In addi-
tion, the cytokine levels in the MDP + LPS group were signiﬁcantly
higher than in the LPS group andwith regard to IL-6 and TNF-awere
even larger than in the FK565 + LPS group (Fig. 5C and D). The cyto-
kine levels in the FK565 + LPS groupwere increased compared to LPS
for all measured cytokines except TNF-a.
Twenty-six hours after treatment, the circulating levels of IFN-c,
IL-1b, IL-6 and TNF-ahad largely decreased in all groups studied and
were below the detection limit inmany samples (Fig. 5E–H). As seen
3 h post-treatment, the highest levels of IFN-c, IL-1b and TNF-a
were recorded in theMDP + LPS treatment group,with a trend being
evident for TNF-a (U = 7.000, p = 0.054, Bonferroni correction). IL-6
remained signiﬁcantly increased in all treatment groups (LPS:
U = 3.000, p = 0.018; Bonferroni correction, MDP + LPS: U = 2.000,
p = 0.018, Bonferroni correction; FK565 + LPS, U = 2.000, p = 0.012,
Bonferroni correction), comparable levels being seen in the
MDP + LPS and FK565 + LPS treatment groups (Fig. 5G).3.6. Effects of MDP, FK565 and LPS alone and in combination on
cytokine mRNA expression in the brain
The expression of cytokine mRNAs in the brain was measured 3
and 26 h after injection of the PRR agonists in order to analyze
cytokine expression at the time of predominant sickness and
depression-like behavior, respectively (Fig. 6). When cytokine
mRNA was assessed 3 h post-treatment, two-way ANOVA revealed
a NOD  LPS interaction for the expression of IFN-c mRNA
(F(2,42) = 5.911, p < 0.01) and a trend for IL-6 mRNA expression
(F(2,42) = 2.774, p = 0.07). Post-hoc analysis disclosed that while nei-
therMDP (3 mg/kg), FK565 (0.003 mg/kg) nor LPS (0.1 mg/kg) alone
increased mRNA expression of IFN-c or IL-6, combined treatment
with MDP + LPS or FK565 + LPS increased IFN-c and IL-6 mRNA
expression compared to LPS or MDP and FK565, respectively
(Fig. 6A and C). In contrast, expression of IL-1bmRNA depended on
LPS (F(1,42) = 24.984, p < 0.001) and the NOD agonistsTable 1
Effects of LPS (0.1 mg/kg), MDP (3 mg/kg) + LPS and FK565 (0.003 mg/kg) + LPS on depress
VEH LPS
FST
Immobility 237.70 ± 30.34 242.14 ± 22
Swimming 108.25 ± 28.95 102.15 ± 21
Climbing 14.07 ± 2.04 15.75 ± 4.3
TST
Immobility 261.25 ± 11.71 241.93 ± 7.3
Swinging 40.58 ± 6.89 55.13 ± 7.4
Curling 58.19 ± 5.49 62.96 ± 5.7
Mice were injected i.p. with saline (VEH), LPS, MDP + LPS or FK565 + LPS in two separa
housed, while the mice exposed to the TST (25.5 h post-treatment) were kept in groups of
6 min test session is expressed in seconds. The values are means ± SEM, n = 7–8.(F(2,42) = 3.174, p 6 0.05) without a signiﬁcant interaction (Fig. 6B).
Likewise, TNF-a mRNA expression depended on LPS (F(1,42) =
25.735, p < 0.001) and the NOD agonists (F(2,42) = 8.535, p < 0.001)
without a signiﬁcant interaction (Fig. 6D).
Twenty-six hours after treatment, cerebral IFN-cmRNA expres-
sion had returned to basal levels in all treatment groups (Fig. 6E).
Conversely, the expression of IL-1b mRNA remained signiﬁcantly
increased in response to MDP + LPS and FK565 + LPS
(F(3,26) = 11.341, p < 0.001) and enhanced by trend in the LPS group
(p = 0.085). In addition, IL-1b mRNA expression was signiﬁcantly
higher in the MDP + LPS group compared to the LPS group (Fig. 6F).
Likewise, TNF-amRNAexpressionwas increased in every treatment
group (F(3,26) = 9.588, p < 0.001), with the highest expression seen in
the MDP + LPS group (Fig. 6H). In contrast, IL-6 mRNA expression
was decreased in all treatment groups (F(3,26) = 13.621, p < 0.001)
(Fig. 6G).3.7. Effects of MDP, FK565 and LPS alone or in combination on
circulating levels of corticosterone and the kynurenine/tryptophan
ratio
The PRR agonists under study had a distinct effect to enhance
the plasma levels of corticosterone as measured 3 h after injection.
Two-way ANOVA revealed a signiﬁcant main factor effect for LPS
(F(1,40) = 76.581, p < 0.001) and the NOD agonists (F(2,40) = 16.608,
p < 0.001) without a signiﬁcant interaction. Post-hoc analysis of
the main factor effects disclosed that FK565 increased circulating
corticosterone compared to VEH and MDP (Fig. 7A).
One day after treatment, the plasma levels of corticosterone
were examined 30 min after exposure to the TST. Under these con-
ditions, the circulating levels of corticosterone were enhanced in
the MDP + LPS treatment group relative to the vehicle (but not
LPS) treatment group and remained unchanged in the LPS and
FK565 + LPS treatment groups (F(3,26) = 4.282, p < 0.05) (Fig. 7B).
The plasma kynurenine/tryptophan ratio, measured 26 h after
treatment, was signiﬁcantly increased following injection of LPS,
MDP + LPS and FK565 + LPS (F(3,26) = 10.160, p < 0.001), this increase
being more pronounced after treatment with MDP + LPS. Particu-
larly, the plasma kynurenine/tryptophan ratio in the MDP + LPS
treatment group was signiﬁcantly larger than in the LPS-treated
group (Fig. 7C).
A similar picture emerged for the circulating levels of kynuren-
ine (Fig. 7D). Kynurenine levels were increased by LPS, MDP + LPS
and FK565 + LPS (F(3,26) = 12.098, p < 0.001). As for the kynuren-
ine/tryptophan ratio, the kynurenine levels in the MDP + LPS group
were signiﬁcantly higher than in the LPS group, while the levels in
the FK565 + LPS group were increased by trend only compared to
LPS alone (p = 0.077). The levels of tryptophan were increased by
MDP + LPS and FK565 + LPS, while LPS alone did not change the
plasma tryptophan levels (F(3,26) = 11.207, p < 0.001) (Fig. 8E).ion-like behavior in the FST and TST 1 day post-treatment in male mice.
MDP + LPS FK565 + LPS
.55 285.91 ± 13.11 292.27 ± 9.16
.77 65.71 ± 13.06 53.95 ± 9.57
8 8.40 ± 2.15 13.81 ± 4.86
3 252.43 ± 12.72 232.01 ± 10.19
8 60.19 ± 15.74 56.94 ± 6.41
9 47.40 ± 6.55 71.07 ± 8.36
te experiments. The mice subjected to the FST (21 h post-treatment) were singly
2. The duration of immobility, swimming, climbing, swinging and curling during the
Fig. 5. Effects of MDP (3 mg/kg), FK565 (0.003 mg/kg) and LPS (0.1 mg/kg) on circulating cytokine levels 3 h (A–D) and 26 h (E–H) after treatment of male mice. Mice were
injected i.p. with saline (VEH), MDP, FK565, LPS, MDP + LPS or FK565 + LPS. Plasma was collected 3 h (A–D) or 26 h (E–H) later. Circulating levels of IFN-c (A + E), IL-1b (B + F),
IL-6 (C + G), and TNF-a (D + H) were measured. Note that the scale of the ordinate is different between the 2 time points. The values are means + SEM, n = 7–8. (A–D): Post-hoc
analysis of signiﬁcant NOD  LPS interactions in 2-way ANOVA: ⁄p < 0.05, versus VEH. #p < 0.05, ##p < 0.01, MDP + LPS versus MDP or FK565 + LPS versus FK565. §p < 0.05,
§§p < 0.01, MDP + LPS or FK565 + LPS versus LPS. Up < 0.05, UUp < 0.01, MDP + LPS versus FK565 + LPS. (E–H): One-way ANOVA: ⁄p < 0.05, ⁄⁄p < 0.01, versus VEH.
Fig. 6. Effects of MDP (3 mg/kg), FK565 (0.003 mg/kg) and LPS (0.1 mg/kg) on cytokine mRNA expression in the brain 3 h (A–D) and 26 h (E–H) after injection in male mice.
Mice were injected i.p. with saline (VEH), MDP, FK565, LPS, MDP + LPS or FK565 + LPS. Expression of IFN-c (A + E), IL-1b (B + F), IL-6 (C + G), and TNF-a (D + H) was measured
3 h (A–D) or 26 h (E–H) after injection. The values are means + SEM, n = 7–8. (A–D): Post-hoc analysis of signiﬁcant NOD  LPS interactions in 2-way ANOVA: #p < 0.05,
##p < 0.01, MDP + LPS versus MDP or FK565 + LPS versus FK565. §p < 0.05, §§p < 0.01, MDP + LPS and FK565 + LPS versus LPS. Main factor effects without NOD  LPS
interactions: ap < 0.01, LPS versus VEH. bp < 0.05, bbp < 0.01, NLR agonists versus VEH. (E–H): One-way ANOVA: +p < 0.1, ⁄p < 0.05, ⁄⁄p < 0.01, versus VEH or as indicated by the
brackets.
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signiﬁcantly higher than in the LPS group.
3.8. Effects of MDP and LPS (0.83 mg/kg) alone and in combination on
c-Fos expression in the brain
In order to analyze brain circuits that are associated with the
observed effects of MDP (3 mg/kg) and LPS (0.83 mg/kg), the
expression of c-Fos was studied by immunohistochemistry in
select brain areas involved in sickness.
Two-way ANOVA revealed a signiﬁcantNOD  LPS interaction in
the PVN (F(1,11) = 18.810, p < 0.001), insula (F(1,13) = 6.940, p < 0.05)
and SO (F(1,13) = 17.496, p 6 0.001) and an interaction approaching
signiﬁcance in the BNSTv (F(1,15) = 4.257, p = 0.057). Post-hoc analy-
sis disclosed that MDP alone did not change c-Fos expression inthese areas, while LPS alone increased c-Fos expression in the BNSTv
and PVN compared to VEH (Fig. 8A and C). In contrast, MDP + LPS
increased c-Fos expression in all 4 areas relative to MDP or LPS
(Fig. 8A, C, E and F).
While LPS had a signiﬁcant main factor effect in all other areas
under study (BNSTd: F(1,13) = 16.883, p < 0.001; CeA: F(1,15) =
80.556, p < 0.001; SFO: F(1,14) = 11.334, p < 0.01; DG: F(1,15) =
39.727, p < 0.001), a signiﬁcantmain factor effect of theNODagonist
MDP was evident in the CeA (F(1,15) = 14.296, p < 0.01) and by trend
in the BNSTd (F(1,13) = 3.237, p < 0.1) (Fig. 8B, D, G and H). The effect
of MDP + LPS to increase the number of c-Fos positive cells in the
SFO, relative to LPS, was statistically not signiﬁcant (Fig. 8G).
Representative micrographs showing the effects of MDP, LPS
and MDP + LPS on the expression of c-Fos in the cerebral areas
under study are shown in Fig. 9.
Fig. 7. Effects of MDP (3 mg/kg), FK565 (0.003 mg/kg) and LPS (0.1 mg/kg) on circulating corticosterone (CORT) levels 3 h (A) and 26 h (B) after treatment, as well as on the
kynurenine/tryptophan (KYN/TRP) ratio (C) and circulating levels of kynurenine (D) and tryptophan (E) measured 26 h after treatment of male mice. Plasma CORT was
measured 3 h after treatment (A) and 26 h after treatment, 30 min following exposure to tail suspension stress (B). Likewise, plasma kynurenine and tryptophan (C–E) were
determined 26 h after treatment, 30 min following exposure to tail suspension stress. The values are means + SEM, n = 7–8. (A): Main factor effects without NOD  LPS
interactions: ap < 0.001, LPS versus VEH. bp < 0.001, FK565 versus VEH or MDP. (B–E): One-way ANOVA: +p < 0.1, ⁄p < 0.05, ⁄⁄p < 0.01, versus VEH or as indicated by the
brackets.
Fig. 8. Effects of MDP (3 mg/kg), LPS (0.83 mg/kg) and MDP + LPS on c-Fos expression 3 h after treatment of male mice. Mice were injected i.p. with saline (VEH), MDP, LPS or
MDP + LPS. Brains were collected 3 h post-treatment and the expression of c-Fos, a marker of neuronal activation, was measured by immunohistochemistry. The values are
means + SEM, n = 3–5. Post-hoc analysis of signiﬁcant NOD  LPS interactions in 2-way ANOVA: ⁄p < 0.05, ⁄⁄p < 0.01, versus VEH. ##p < 0.01, MDP + LPS versus MDP. §p < 0.05,
§§p < 0.01, MDP + LPS versus LPS. Main factor effects without NOD  LPS interactions: ap < 0.01, LPS versus VEH. bp < 0.01, NLR agonist versus VEH. Abbreviations: BNSTd/
v = bed nucleus of the stria terminalis dorsal/ventral, CeA = central amygdala, DG = dentate gyrus, PVN = paraventricular nucleus of the hypothalamus, SFO = subfornical
organ, SO = supraoptic nucleus.
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This study provides a multivariate assessment of the effects of
the NOD1 agonist FK565 and the NOD2 agonist MDP, alone and
in combination with the TLR4 agonist LPS, on immune, cerebral,
neuroendocrine and behavioral parameters of sickness in male
mice. The results revealed that NOD1 and NOD2 activation inter-
acts with TLR4 agonism in inducing sickness. In analyzing the
nature of this interaction (additive versus synergistic) it wouldhave been desirable to construct dose–response curves, but such
experiments were not deemed acceptable in view of ethical con-
siderations. This disadvantage was balanced by a careful choice
of the compound doses under study, based on the available litera-
ture and the results of pilot experiments. Thus, the NOD agonist
doses were chosen such that they failed to induce sickness by their
own, yet were able to enhance the sickness response to LPS. By
comparing the effects of the PRR agonists alone with those of
FK565 + LPS and MDP + LPS it was disclosed that NOD and TLR4
Fig. 9. Representative micrographs of forebrain regions illustrating c-Fos immunoreactivity induced byMDP (3 mg/kg), LPS (0.83 mg/kg) and MDP + LPS in male mice. The left
column panels show micrographs of forebrain regions taken from saline (VEH)-treated mice euthanized 3 h after injection. The second column panels depict micrographs of
the same brain regions taken from MDP-treated mice, while the third column panels show micrographs of LPS-treated mice. The right column panels represent c-Fos
immunolabeling induced by MDP + LPS 3 h after treatment. The squares in the left column represent the position and size of the ROIs. Abbreviations: BNSTd/v = bed nucleus of
the stria terminalis dorsal/ventral, CeA = central amygdala, DG = dentate gyrus, PVN = paraventricular nucleus of the hypothalamus, SFO = subfornical organ, SO = supraoptic
nucleus.
116 A. Farzi et al. / Brain, Behavior, and Immunity 44 (2015) 106–120agonism interacted with each other either in a synergistic or addi-
tive manner to provoke distinct aspects of sickness. It must not be
neglected, however, that the interaction might have also been
inﬂuenced by differences in the purity, potency and elimination
of the compounds under study.4.1. Effects of NOD1 and NOD2 agonism
FK565 (0.001–0.003 mg/kg) and MDP (1–3 mg/kg), adminis-
tered alone, were largely inactive in eliciting sickness. Thus, they
failed to signiﬁcantly decrease locomotion and exploration in the
A. Farzi et al. / Brain, Behavior, and Immunity 44 (2015) 106–120 117LabMaster system. This ﬁnding is in overall agreement with
reports that NOD2 activation leads only to a slight decline of
locomotion (Fosset et al., 2003; Engeland et al., 2003). Food intake
in the LabMaster system remained likewise unaltered by MDP.
MDP has been reported to reduce food intake at 1.6 mg/kg in rats,
while a dose of 0.6 mg/kg was ineffective (Biberstine and
Rosenthal, 1994; Fosset et al., 2003; Langhans et al., 1990). Thus,
the dose of 1 mg/kg MDP used here might have been too low to
affect ingestion. In addition, murine macrophages are less suscep-
tible to MDP than rat macrophages, indicating species differences
in the sensitivity to MDP (Nagao et al., 1990). However, this argu-
ment is relativized by the ﬁnding that a higher dose of MDP (3 mg/
kg) given to double-housed mice outside the LabMaster system
failed to cause weight loss within 1 day after treatment. This obser-
vation is in keeping with studies in rats in which MDP failed to
reduce body weight (Cloutier et al., 2012; Engeland et al., 2003)
although weight gain may be decreased (Biberstine and
Rosenthal, 1994). FK565 (0.001 mg/kg) reduced food intake by
trend when given to single-housed mice, whereas no appreciable
weight loss was observed 21 h after injection of a higher dose of
FK565 (0.003 mg/kg) in double-housed animals. It has previously
been reported that body weight decreases after an injection of
6 mg/kg FK565 (Izumi et al., 1983).
The lack of a sickness response to FK565 andMDP alonewas par-
alleled by a failure of these NOD agonists to signiﬁcantly augment
circulating cytokine levels 3 h after injection. FK565, however, but
not MDP, signiﬁcantly increased circulating corticosterone, which
indicates that the NOD1 agonist stimulated the HPA axis, a compo-
nent of the sickness response (Lenczowski et al., 1997). Since brain
cytokine expression was comparable between FK565 and MDP, it
appears unlikely that the FK565-evoked rise of plasma corticoste-
ronewasmediated by cytokines. Since nitric oxide (NO) participates
in the activation of the HPA axis (Bugajski et al., 2004) and FK565 is
more potent in inducing NO than MDP (Cartwright et al., 2007), NO
may be a mediator of the cytokine-independent HPA axis stimula-
tion due to NOD1 agonism.
As MDP and FK565 were also unable to change body tempera-
ture, anxiety-like behavior and SP, we conclude that stimulation
of NOD1 and NOD2 alone, with doses of FK565 and MDP that
enhance the effects of LPS, is insufﬁcient to evoke an overt sickness
response.
4.2. Effects of combined NOD1 or NOD2 plus TLR4 agonism in causing
sickness
Interaction and crosstalk between the signaling pathways of
TLRs and NLRs lead to increased or decreased production of proin-
ﬂammatory cytokines, depending on the cell type tested (Elinav
et al., 2011). Pretreatment of monocytic cells with NOD agonists
can facilitate the LPS-induced production of various cytokines
(Chamaillard et al., 2003; Fritz et al., 2005; Park et al., 2007;
Uehara et al., 2005), and a similar synergistic increase of cytokine
production following exposure to NLR and TLR agonists is seen
in vivo (Parant et al., 1995; Shikama et al., 2011). Furthermore, prim-
ing with MDP enhances anaphylactoid reactions and lethality
evoked by LPS (Takada and Galanos, 1987; Takada et al., 1990),
while intravenous administration of FK565 alone has been reported
to elicit signs of septic shock in rats (Cartwright et al., 2007). Priming
withMDP can also aggravate the reduction of ingestion and locomo-
tion induced by LPS in rats (Engeland et al., 2003; Langhans et al.,
1990), whereas the behavioral effects of combined NOD1 and
TLR4 agonism remained unexplored.
The ability of NLR agonism to aggravate and prolong the sick-
ness response to LPS is particularly highlighted by the LabMaster
data. Speciﬁcally, the low dose of 0.1 mg/kg LPS was able to
decrease only locomotion and ingestion, while the combinationof FK565 + LPS and MDP + LPS aggravated and prolonged the
effects of LPS on all parameters tested (locomotion, exploration,
ingestion, SP) and led to a signiﬁcant decrease of locomotion,
exploration (rearing) and food intake for 2–3 days. In contrast, SP
was decreased for a shorter period of time.
The LabMaster results also shed some light on the effect of sin-
gle housing in immune–brain interactions. Housing conditions can
modify affective behavior (Painsipp et al., 2011), and single hous-
ing made the animals more vulnerable by the PRR agonists. While,
in line with the literature (Frenois et al., 2007), novelty-induced
locomotion in the OF was not altered 1 day after treatment with
0.1 mg/kg LPS, home cage activity in the LabMaster was decreased
for a longer period. Since avoidance of physical activity is a sensi-
tive indicator of illness (Skinner et al., 2009), fatigue and lethargy
appear to persist for a longer period than revealed by the
novelty-induced locomotion paradigm, although the different test-
ing conditions may also contribute to the different outcomes. The
timing of the experiments with regard to the light–dark cycle
might be a further explanation for the differences observed inside
and outside the LabMaster system. Thus home cage behavior in the
LabMaster system was monitored during the whole light–dark
cycle, while the behavioral tests were conducted during the light
phase when activity levels are generally lower. The SP test has
been used to measure anhedonia as an indication of depression-
like behavior at a time point when food intake had already normal-
ized (Frenois et al., 2007). However, the LabMaster data indicate
that the anorexic effect of LPS outlasts its anhedonic effect. Our
observation is backed by other studies in which the duration of
LPS-induced sickness has been found to overlap with that of
depression-related behavior (Biesmans et al., 2013).
A decrease in locomotion and exploration can also reﬂect vis-
ceral hyperalgesia due to inﬂammatory processes (Schwartz
et al., 2013). In line with this contention, LPS has been shown to
evoke acute pain (Kamei et al., 2004) although it has also been
reported to induce analgesia via activation of opioid receptors
(Yirmiya et al., 1994). Likewise, the cytokine-independent analge-
sic effect of MDP and FK565 is blocked by the opioid receptor
antagonist naloxone (Sato et al., 2010). It thus seems unlikely that
the behavioral response to combined NLR and TLR4 agonism
reﬂects hyperalgesia, but this issue needs further investigation.
Enhanced depression-like behavior has been observed in mice
24 h after injection of LPS (0.83 mg/kg) when the sickness behavior
has largely vanished (Frenois et al., 2007). As shown here, the dose
of 0.1 mg/kg LPS was too low to induce depression-like behavior in
the FST, which is in accordance with the literature (Deak et al.,
2005). The combination of FK565 or MDP plus 0.1 mg LPS nomi-
nally prolonged the time spent immobile in the FST, which attests
to a facilitatory effect in the development of depression at this low
dose of LPS.
Striking differences between the effects of single and combined
administration of NLR and TLR agonists were seen with regard to
body temperature. While LPS alone did not induce any change as
measured 4 h post-treatment, the combination of FK565 or MDP
with 0.83 mg/kg LPS induced overt hypothermia, while the combi-
nation with 0.1 mg/kg LPS caused only a slight decrease of body
temperature. The thermoregulatory response to LPS in rodents
depends on its dose, the route of administration and ambient tem-
perature (Rudaya et al., 2005). At ambient temperatures below
thermoneutrality mice develop mild hypothermia at intermediary
doses of LPS and excessive hypothermia at high doses, indicative of
a septic shock-like condition (Krakauer et al., 2010). The interac-
tion of NLR and TLR agonists in augmenting hypothermia is in line
with the aggravation and prolongation of sickness observed in the
LabMaster and OF. Thus, the combination of FK565 or MDP plus
0.83 mg/kg LPS decreased novelty-related locomotion (total dis-
tance traveled) in the OF 21 h post-treatment compared to LPS.
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LPS (0.1 mg/kg), being devoid of an effect on locomotion, was
tested. This increase in anxiety-like behavior was more pro-
nounced after treatment with FK565 + LPS, but not MDP + LPS.
The seemingly paradox observation that LPS alone increased anxi-
ety-like behavior at the 0.1, but not 0.83 mg/kg dose may be
explained by the surmise that any change in anxiety-like behavior
is masked by the decrease in locomotion evoked by 0.83 mg/kg
LPS.
4.3. Potential mechanisms of the synergistic effects of NLR and TLR
agonists on sickness
In order to shed light on potential mechanisms whereby FK565
and MDP aggravate LPS-induced sickness, several peripheral and
cerebral factors were analyzed. Expression of c-Fos in brain regions
known to respond to immune stimulation (Frenois et al., 2007) was
used to examine whether the exaggerated sickness response to
MDP + LPS (0.83 mg/kg) is reﬂected by pertinent changes of neuro-
nal activity in the brain. Being the product of an immediate early
gene, c-Fos is rapidly but transiently expressed following neuronal
activation (Rivest and Laﬂamme, 1995) and therefore was mea-
sured 3 h after immune stimulation. LPS alone induced c-Fos
expression in brainstem-derived ascending pathways to forebrain
immune-responsive nuclei (Gaykema and Goehler, 2011). Priming
with MDP enhanced the number of c-Fos positive neurons in an
additive or synergistic manner depending on the area examined.
Thus the increase of c-Fos expression in the BNSTd and CeA was
additive, while synergistic increases of c-Fos expression were
observed in the BNSTv, PVN, insula and SO. These observations
indicate that the synergistic effect of NOD2 and TLR4 stimulation
on the sickness response is related to enhanced neuronal activation
in relevant brain nuclei. Of particular interest was the observation
that LPS, administered in the absence or presence of MDP,
decreased the number of c-Fos positive cells in the dentate gyrus
of the hippocampus, which has been associated with a decrease
of exploratory behavior following treatment with LPS (Gaykema
and Goehler, 2011).
Although the HPA axis participates in the sickness response
(Lenczowski et al., 1997), the current results indicate that the
HPA axis did not contribute to the aggravation of sickness by com-
bined NLR + TLR agonism, since neither FK565 nor MDP augmented
the LPS-induced rise of plasma corticosterone, both in the absence
of stress and following exposure to tail suspension stress.
In contrast, proinﬂammatory cytokines in the plasma and brain
are very likely to mediate the exacerbation of sickness due to NLR
plus TLR agonism. Consistent with the interaction of FK565 and
MDP with LPS in innate immune cells (Le Contel et al., 1993;
Netea et al., 2005; Wang et al., 2001; Wolfert et al., 2002), the
LPS-evoked rise of plasma cytokines 3 h post-treatment was syner-
gistically enhanced by priming with FK565 or MDP.
In parallel with their peripheral induction, the cerebral expres-
sion of IFN-c and IL-6, was synergistically enhanced by
FK565 + LPS and MDP + LPS, while the increase of cerebral IL-1b
and TNF-a mRNA expression was rather additive. Thus, the effects
of NOD agonists to prime the production of proinﬂammatory cyto-
kines in response to LPS exhibit different patterns of interaction in
the periphery and brain, depending on the compounds investi-
gated. While this interaction is of a primarily synergistic nature
in the periphery, the interaction in the brain can either be of an
additive or synergistic manner. This different pattern of interaction
is also reﬂected by different time courses of cytokine induction in
the periphery and brain. While the PRR-evoked increase in plasma
cytokines had largely waned 1 day post-treatment, the cerebral
expression of IL-1b and TNF-a mRNA was still elevated. The most
striking difference was seen with IL-6, the plasma levels of whichremained elevated 1 day after treatment with LPS, MDP + LPS and
FK565 + LPS, whereas the cerebral expression of IL-6 mRNA was
reduced by these treatments, as previously described for LPS
(Andre et al., 2008; Bay-Richter et al., 2011).
Collectively, our ﬁndings suggest that the sickness response to
combined NLR and TLR agonism is initiated by immune stimula-
tion which in turn activates secondary mechanisms that drive
illness. Kynurenine may play such a role, given that its plasma level
was signiﬁcantly more enhanced by the combination treatments
than by LPS alone and remained signiﬁcantly elevated 1 day
post-treatment. In line with this contention, blockade of IDO
decreases kynurenine levels and abrogates LPS-induced depres-
sion-like behavior without changing brain cytokine expression
(O’connor et al., 2009). Proinﬂammatory cytokines, particularly
IFN-c and TNF-a, activate IDO and lead to the conversion of tryp-
tophan to kynurenine which in rodents elicits depression-like
behavior (O’connor et al., 2009). The increase in plasma tryptophan
seen here contrasts with a decrease of tryptophan seen in other
studies (O’connor et al., 2009) but may be related to the TST
employed 30 min before blood sampling, given that stress can
increase peripheral tryptophan levels in rodents, but the underly-
ing mechanisms are not understood (Dunn, 1988; Malyszko
et al., 1995). It is, however, emerging that not tryptophan depletion
but kynurenine production contributes to the behavioral effects of
immune activation (O’connor et al., 2009). Although peripheral
tryptophan may decrease in response to LPS, the availability of
tryptophan to the brain remains unchanged and brain tryptophan
may even increase (O’connor et al., 2009).
Both NOD1 and NOD2 agonists enhanced the sickness response
to LPS in a grossly similar manner, which is surprising in view of
the differences in the expression, distribution and function of these
PRRs and in the sources and afﬁnities of their agonists (Dharancy
et al., 2010; Hsu et al., 2008; Masumoto et al., 2006; Sabbah
et al., 2009). Thus, NOD1 is more widely expressed than NOD2
and occurs in peripheral and cerebral tissues (Inohara et al.,
1999), while NOD2 expression is largely restricted to monocytes
(Ogura et al., 2001). In line with these ﬁndings, cytokine levels
were generally higher after treatment with MDP + LPS, together
with the highest corticosterone levels and the kynurenine/trypto-
phan ratio in this group 1 day post-treatment, pointing to a rela-
tionship between cytokine expression, corticosterone release and
kynurenine formation. In contrast, the behavioral effects were ten-
dentially more pronounced after treatment with FK565 ± LPS.
These disparities may arise from differential interactions of
NOD1 and NOD2 with TLR4 at the blood–brain interface. On the
one hand, NOD1, but not NOD2, is expressed in the choroid plexus
and other circumventricular organs (Inohara et al., 1999), which
may also account for the particular ability of FK565 to enhance cir-
culating corticosterone. On the other hand, the cerebral effects of
peripherally injected LPS may be mediated by TLR4 on CNS-
resident cells and be independent of systemic cytokine effects
(Chakravarty and Herkenham, 2005; Murray et al., 2011). In addi-
tion, LPS is able to induce a transient rise of intracellular calcium in
microglial cells of the area postrema, while MDP is devoid of such
an effect, again pointing to absent NOD2 expression at this circum-
ventricular organ (Wuchert et al., 2008).
4.4. Conclusions
The current study shows that NOD1 and NOD2 activation alone
has only minor effects on cytokine production and sickness behav-
ior but potently synergizes with TLR4 stimulation in aggravating
and prolonging illness. Analysis of the potential mechanisms led
us to conclude that the aggravation of sickness is associated with
enhanced production of proinﬂammatory cytokines in the periph-
ery and brain, increased kynurenine formation and activation of
A. Farzi et al. / Brain, Behavior, and Immunity 44 (2015) 106–120 119immune responsive brain nuclei. Further studies are warranted to
analyze whether NOD1 and TLR4 interact with each other primar-
ily at the blood–brain interface while NOD2 and TLR4 synergism
occurs primarily in hematopoietic cells. Under conditions of infec-
tion or an imbalance in microbiota-host interaction, NLRs and TLRs
are likely to be targeted in parallel by an expanded number of PRR
agonists. It remains to be investigated whether the concentrations
of endogenous PRR agonists occurring in infection give rise to a
similar synergism of NLRs and TLRs as seen here with FK565,
MDP and LPS. We propose that the interaction of NLRs and TLRs
in boosting a multidimensional sickness response reﬂects an
important immunological and neurobiological mechanism of
protection from microbial invasion.
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